Monitor the full Q3 2026 10-Q for actual TONMYA revenue, total product revenue, operating expenses, and cash burn rate. The sequential revenue growth is encouraging, but the cash runway into early Q2 2027 implies continued dilution risk.
Price Chart
Executive Summary
Tonix Pharmaceuticals disclosed preliminary Q3 2026 TONMYA net revenue of $14M-$15M, up 27-36% sequentially from Q2's $11M, and estimated cash of $162.8M. The TONMYA growth trajectory is positive, but the company remains pre-profitability with cash burn of ~$84.6M in H1 2026, and the preliminary nature of the data introduces uncertainty.
Key Financial Metrics
Key Facts
- Q3 2026 TONMYA net revenue estimated between $14.0M and $15.0M, up 27-36% sequentially from Q2 2026's $11.0M
- Cash and cash equivalents estimated at $162.8M as of September 30, 2026, down from $176.2M at June 30, 2026
- Data is preliminary and subject to revision upon completion of quarter-end closing procedures
- Prior Q2 2026 net loss was $40.6M with operating cash burn of $84.6M in H1 2026
Financial Impact
TONMYA revenue growth of 27-36% QoQ to $14M-$15M range; cash burn of ~$13.4M in Q3 2026 (from $176.2M to $162.8M)
Risk Factors
- Preliminary data may be materially revised upon completion of financial closing procedures
- Cash burn of ~$13.4M per quarter suggests runway only into early Q2 2027, requiring additional financing
- Company remains pre-profitable with significant operating losses
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047139 |
| Document: 0001493152-26-047139-index-headers.html | 0001493152-26-047139 |
| Document: 0001493152-26-047139-index.html | 0001493152-26-047139 |
| Document: 0001493152-26-047139.txt | 0001493152-26-047139 |
| 8-K Data (Synthetic) | 0001493152-26-047139 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $5.73 | awaiting T+20 | — | $5.30 (−7.50%) |
Oct 15, 2026 11d ago | 8-K | $6.42 | awaiting T+20 | — | $5.30 (−17.45%) |
Oct 2, 2026 23d ago | 8-K | $8.07 | awaiting T+20 | — | $5.30 (+34.32%) |
Sep 22, 2026 4w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.30 (−49.95%) |
Sep 8, 2026 6w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.30 (−59.73%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.30 (−57.90%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.30 (−50.33%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.30 (−48.89%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.30 (−54.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers